Esmolol, sold under the brand name Brevibloc, is a cardio selective beta1 receptor blocker with rapid onset,[3] a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages.

[6] To terminate supraventricular tachycardia, Episodic atrial fibrillation or flutter, Arrhythmia during anaesthesia, To reduce HR and BP during and after cardiac surgery, and In early treatment of myocardial infarction.

Total body clearance in man was found to be about 20 L/kg/hr, which is greater than cardiac output; thus the metabolism of esmolol is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow.

Esmolol's short duration of action is based on the ester-methyl side chain which allows for quick hydrolysis.

[citation needed] Esmolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier.